The Biliary Tumor Market to reach $6.1 Billion by 2030; Rising incidence of biliary cancers, advancements in diagnostic technologies, increasing adoption of targeted therapies and immunotherapies, rising focus on minimally invasive treatment options,

The Biliary Tumor Market size is estimated to reach $6.1 Billion by 2030, growing at a CAGR of 5.7% during the forecast period 2024-2030, according to a recent report published by IndustryARC, titled, “Biliary Tumor Market – By Diagnosis Type (Imaging Techniques, Endoscopic Techniques, Biopsy, Blood Tests, Others), By Drug Class (Chemotherapy Drugs, Targeted Therapy Drugs, Immunotherapy Drugs, Radiopharmaceuticals), By Stage of Cancer (Early-Stage Tumors, Locally Advanced Tumors, Metastatic Tumors), By Age Group (Below 40 Years, 40-60 Years, Above 60 Years), By Treatment Type (Surgical Treatment, Chemotherapy, Radiation Therapy, Targeted Therapy, Immunotherapy, Others), By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Research & Academic Institutions, Others), By Geography - Global Opportunity Analysis & Industry Forecast, 2024-2030”

The rising incidence of biliary cancers is increasing demand for treatments. Advancements in diagnostic technologies are improving early detection. Targeted therapies and immunotherapies are being increasingly adopted. Minimally invasive treatment options are gaining popularity for faster recovery. The aging population is driving higher demand for biliary tumor treatments. Research and development activities are expanding the treatment landscape. Favorable reimbursement policies are improving access to advanced therapies. 

North America accounted for the largest share of 35% of the Biliary Tumor Market in 2023 The biliary tumor market is led by North America because of its higher prevalence of bile duct and gallbladder cancers, and the presence of advanced healthcare infrastructure. That’s about 23,000 people in the U.S. that are diagnosed with biliary tract cancers (BTC) every year, which is a serious regional health issue, according to AstraZeneca. In addition, these cancers are aggressive and survival rates are poor, 5% to 15% of patients survive beyond five years, both of which drive demand for advanced treatments. High spending on healthcare and focus on early detection and innovative therapies make the region the number one market.

The growing aging population is a major driver for the increasing prevalence of biliary tumors. Age is a significant risk factor for the development of biliary tract cancers such as cholangiocarcinoma and gallbladder cancer due to prolonged exposure to chronic inflammation, genetic mutations and comorbidities. According to the UN, the number of people aged 65 years or older worldwide is projected to more than double, rising from 761 million in 2021 to 1.6 billion in 2050. The number of people aged 80 years or older is growing even faster. With the global population of aged individuals rising rapidly, , the incidence of biliary tumors is expected to increase correspondingly.

The rising focus on minimally invasive treatment options is transforming the management of biliary tumors. Techniques such as laparoscopic surgery, endoscopic biliary stenting and radiofrequency ablation (RFA) are gaining traction due to their reduced recovery time, lower complication rates and improved quality of life for patients. These procedures are particularly beneficial for elderly or high-risk patients who are unsuitable for conventional open surgeries. Innovations in imaging and robotic-assisted technologies further enhance the precision of these treatments enabling early intervention and better tumor control. As healthcare providers emphasize patient-centric care, the preference for minimally invasive procedures continues to grow.

• In November 2024, Roche announced that it received FDA approval for its PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody test, into biliary tract cancer (BTC). This approval marks the test as the first FDA-approved companion diagnostic to help identify biliary tract cancer (BTC) patients eligible for Jazz Pharmaceuticals' ZIIHERA.

• In June 2024, Bold Therapeutics announced positive Phase 2 safety and efficacy results for its lead drug, BOLD-100, in treating advanced metastatic biliary tract and gastric cancers.

• In June 2024, Zanidatamab demonstrated durable antitumor activity in patients with previously treated advanced HER2-amplified biliary tract cancer, according to phase 2B HERIZON-BTC-01 study results. 

Key companies profiled in the Biliary Tumor Market are Taiho Oncology, AbbVie Inc., Eli Lilly & Company, Merck KGaA, AstraZeneca, Helsinn Group, Bayer AG, F. Hoffmann-La Roche AG, Fresenius SE & Co. KGaA, Pfizer Inc. and Others